Research

Hormonal

High-dose tirzepatide (10–15 mg/week) is associated with a statistically significant increase in the risk of acute kidney injury (AKI) compared to control treatments.

If you are prescribed high-dose tirzepatide (10-15 mg/week), be aware of a small but statistically significant increased risk of acute kidney injury. Stay well-hydrated, especially if you experience gastrointestinal side effects like nausea or diarrhea, as volume depletion can trigger AKI. Monitor your kidney function as recommended by your doctor, and report any sudden changes in urination or swelling immediately.

ModerateSupportsLOW confidence
Only high-dose tirzepatide (10–15 mg/week) was associated with a significantly increased risk of AKI compared to controls (absolute risk difference: 0.28%; number needed to harm: 357).
Chih-Sung Liang et al. · International Journal of Molecular Sciences · 2026

Why this rating

Based on a network meta-analysis of 67 RCTs, but the specific finding for high-dose tirzepatide is described as 'sparse-event data with wide credible intervals' and 'hypothesis-generating'.

Source

Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis

Chih-Sung Liang et al. · International Journal of Molecular Sciences · 2026

DOI 10.3390/ijms27094137

Meta-analysis · 67 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →